Pharmacy

Jubilant Biosys, a unit of Jubilant Life Sciences, recently       announced that it has received an undisclosed amount as a milestone payment from AstraZeneca for its research on pain management in the neuroscience therapeutic area.  "The collaboration, which was initiated two years ago in neuroscience therapeutic area, has now expanded to cardiovascular and metabolic diseases and focuses on the delivery of a steady stream of pre-clinical outcomes to AstraZeneca by Jubilant," stated a press release by Jubilant Life Sciences. Commenting  on  the development, Sri mosut) CEO & President, Jubilant Global Drug Discovery and Development, said, "We are pleased that we have delivered outcomes and  early success  to the portfolio efforts at AstraZeneca.   This   is the result of excellent collaboration     between scientists at Jubilant and AstraZeneca."

The alliance between Jubilant and London headquartered drug firm AstraZeneca in the neuroscience  therapeutic area began two year ago. AstraZeneca own: the compound; developed under the collaboration with worldwide development and commercialization rights. On the other hand Jubilant derives research funding and success- based development and commercialization milestone payments, added the press release.